Targeting autotaxin impacts disease advance in the SOD1‐G93A mouse model of amyotrophic lateral sclerosis
Open Access
- 28 September 2021
- journal article
- research article
- Published by Wiley in Brain Pathology
- Vol. 32 (3) , e13022
Abstract
A preclinical strategy to broaden the search of potentially effective treatments in amyotrophic lateral sclerosis (ALS) relies on identifying factors controlling motor neuron (MN) excitability. These partners might be part of still unknown pathogenic pathways and/or useful for the design of new interventions to affect disease progression. In this framework, the bioactive membrane‐derived phospholipid lysophosphatidic acid (LPA) affects MN excitability through LPA receptor 1 (LPA1). Furthermore, LPA1 knockdown is neuroprotective in transgenic ALS SOD1‐G93A mice. On this basis, we raised the hypothesis that the major LPA‐synthesizing ectoenzyme, autotaxin (ATX), regulates MN excitability and is a potential target to modulate disease development in ALS mice. We show here that PF‐8380, a specific ATX inhibitor, reduced intrinsic membrane excitability (IME) of hypoglossal MNs in brainstem slices, supporting that baseline ATX activity regulates MN IME. PF‐8380‐induced alterations were prevented by a small‐interfering RNA directed against mRNA for lpa1. These outcomes support that impact of ATX‐originated lysophospholipids on MN IME engages, at least, the G‐protein‐coupled receptor LPA1. Interestingly, mRNAatx levels increased in the spinal cord of pre‐symptomatic (1–2 months old) SOD1‐G93A mice, thus preceding MN loss. The rise in transcripts levels also occurred in cultured spinal cord MNs from SOD1‐G93A embryos, suggesting that mRNAatx upregulation in MNs is an etiopathogenic event in the ALS cell model. Remarkably, chronic administration in the drinking water of the orally bioavailable ATX inhibitor PF‐8380 delayed MN loss, motor deterioration and prolonged life span in ALS mice. Treatment also led to a reduction in LPA1‐immunoreactive patches in transgenic animals mostly in MNs. These outcomes support that neuroprotective effects of interfering with ATX in SOD1‐G93A mice rely, at least in part, on LPA1 knockdown in MNs. Therefore, we propose ATX as a potential target and/or a biomarker in ALS and highlight ATX inhibitors as reasonable tools with therapeutic usefulness for this lethal pathology.Keywords
This publication has 46 references indexed in Scilit:
- The Puzzling Case of Hyperexcitability in Amyotrophic Lateral SclerosisJournal of Clinical Neurology, 2013
- Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Cdk5/p25-Induced Cytosolic PLA2-Mediated Lysophosphatidylcholine Production Regulates Neuroinflammation and Triggers NeurodegenerationJournal of Neuroscience, 2012
- Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to DegenerationNeuron, 2011
- Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyondJournal of Cell Biology, 2009
- Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX‐mediated conversion to LPA, an initiator of neuropathic painJournal of Neurochemistry, 2008
- High Threshold, Proximal Initiation, and Slow Conduction Velocity of Action Potentials in Dentate Granule Neuron Mossy FibersJournal of Neurophysiology, 2008
- Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during DevelopmentMolecular and Cellular Biology, 2006
- Integrative role of cPLA2 with COX‐2 and the effect of non‐steriodal anti‐inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosisJournal of Neurochemistry, 2005
- Cloning, Chromosomal Localization, and Tissue Expression of Autotaxin from Human Teratocarcinoma CellsBiochemical and Biophysical Research Communications, 1996